
The FDA granted RMAT and fast track designations to prizloncabtagene autoleucel , a CD20/CD19 bispecific CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.
Guess the Diagnosis
Guess the Diagnosis: Case 2
Mark F. is a 25-year-old law school student from Florida with a 3-week history of severe fatigue, night sweats, and weight loss; he has also reported high fevers for the past week. He did not complain of joint pain.
The patient was admitted for further assessment.
Mark’s SLE diagnosis was reviewed and further testing was performed:

